Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer

Phase 2 Completed 54 enrolled MedSIR Hoffmann-La Roche · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a multicenter, open-label, non-comparative, three-arm, phase IIa trial of Ipatasertib (GDC-0068) in combination with non-taxane chemotherapy agents for taxane-pretreated unresectable locally advanced or metastatic triple-negative breast cancer patients

Timeline

Start: 2020-10-08
Primary completion: 2023-11-10
Completion: 2023-11-10

Publications

Lopez-Miranda E, Perez-Garcia JM, Gion M, Ribelles N, Cortez-Castedo P, Alonso-Romero JL, Garcia MM, Gonzalez-Santiago S, Bermejo B, Morales S, Caranana V, Garrigos L, Fernandez-Pinto M, Garcia-Vicente S, Garcia-Sanz A, Mena-Molina A, Boix O, Alcala-Lopez D, Llombart-Cussac A, Cortes J. Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial. Breast Cancer Res. 2025 Aug 6;27(1):141. doi: 10.1186/s13058-025-02089-4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Capecitabine	Small molecule	1000 mg/m2	Oral
Subject	Carboplatin	Small molecule	5 unknown	Intravenous
Subject	Eribulin	Small molecule	1.23 mg/m2	Intravenous
Subject	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Subject	Ipatasertib	Small molecule	400 mg	Oral

Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer

Summary

Timeline

Publications

Drugs

Indications